Case Report

Intravitreal bevacizumab in congenital retinal macrovessel with retinal arteriolar macroaneurysm

Neha Goel *,1; Vinod Kumar 2; Anisha Seth; Basudeb Ghosh

Abstract

Congenital retinal macrovessel (CRM) refers to an aberrant vessel, usually a vein, which traverses the macula and supplies both sides of the horizontal raphe. It is a rare condition, mostly asymptomatic and discovered on routine examination. We describe a case of both arterial and venous CRM with a macroaneurysm along the arterial CRM that presented with decreased vision due to prominent lipid exudation at the macula. Treatment with intravitreal bevacizumab resulted in a favourable anatomical as well as functional outcome. To the best of our knowledge, this is the first report of this unusual presentation of CRM, and its successful management with intravitreal bevacizumab.

Keywords: Congenital retinal macrovessel, Retinal artery macroaneurysm, Intravitreal bevacizumab

Introduction

The term “congenital retinal macrovessel” (CRM) was coined by Brown et al. to describe an aberrant retinal vessel, frequently a vein, crossing the central macula and supplying or draining both above and below the horizontal raphe. The condition is usually unilateral, and rarely affects visual acuity.1,2 We hereby describe an unusual case of arterial as well as venous CRM which was associated with reduction in vision. This was attributed to macular exudation from a macroaneurysm along the arterial CRM. The patient was treated successfully with intravitreal bevacizumab. To the best of our knowledge, this is the first report of intravitreal bevacizumab in retinal arteriolar macroaneurysm associated with CRM.

Case report

A 65 year old female presented with complaints of blurred vision in her left eye since one month before. She had poor vision in her right eye following cataract surgery done 12 years back. She was a hypertensive well controlled by medication. On examination, her right eye had no light perception, due to aphakic bullous keratopathy and secondary glaucoma. The best corrected visual acuity (BCVA) in her left eye was 20/200. Anterior segment examination including intraocular pressure was unremarkable apart from the presence of a posterior chamber intraocular lens. Dilated fundus examination revealed prominent lipid exudation with aberrant vessels at the centre of the macula (Fig. 1a). Fluorescein angiography showed an arterial CRM arising from the superior branch of the central retinal artery (Fig. 1b) and a venous CRM draining into the inferior branch of the central retinal vein before bifurcation (Fig. 1c). A small macroaneurysm was present along the arterial CRM just temporal to the temporal margin of the optic disc (Fig. 1c and d). There were prominent retinal vascular calibre abnormalities of the superotemporal retinal artery which anastomosed with the numerous branches of the venous CRM. In addition, there was markedly increased...
branching and anastomosis of vessels in the perifoveal area. This anomalous capillary network contained multiple pin
point leaks, especially the nasal to the fovea (Fig. 1d). No
capillary nonperfusion areas were noted. Spectral domain
optical coherence tomography (SD-OCT) was performed
and showed intraretinal hard exudates along with retinal
oedema in the nasal part of the macula (Fig. 2a and b).

After being informed about the off-label use of intravitreal
bevacizumab as a treatment option, the patient agreed to
receive an intravitreal injection of bevacizumab (1.25 mg in
0.05 ml) in her left eye. At one month follow up, BCVA
improved to 20/60 with marked decrease in the hard
exudates and macular oedema. A second injection of intravitreal
bevacizumab was administered. At one month following the
second dose, BCVA improved to 20/30 with further reduction
in retinal hard exudates (Fig. 2c). SD-OCT confirmed the
decrease in macular oedema and hard exudates and revealed
normalization of the foveal contour (Fig. 2d). This picture was
maintained till two years follow up with no recurrences.

Discussion

A large retinal vessel crossing the horizontal raphe in the
macular area is termed as a CRM. Since the first description
in 1869 by Mauthner, fewer than 50 cases have been
reported. A CRM is usually a retinal vein, rarely it could be
an artery or both artery and vein. Our case had both arterial
as well as venous CRM; this has been described rarely in
literature.1,2

CRMs are usually benign and stable and are mostly
detected in asymptomatic patients on routine examination.

Occasionally, a CRM can present with decreased vision which
has been attributed to haemorrhage, foveal cyst, the vessel
itself crossing the fovea1,2 and central serous chorioretinopa-
thy.4 Our case presented with a macroaneurysm along the
arterial CRM and prominent macular exudation, with retinal
oedema. Only 2 case reports of arterial CRM with a leaking
macroaneurysm affecting visual acuity were found in litera-

ture.5,6 Koizumi et al. also described a retinal arteriolar
macroaneurysm and CRM, however, both lesions were dis-
tinct and unrelated.7

Macroaneurysms are acquired dilatations of the retinal
arteries that usually occur in elderly hypertensive women. It
has been suggested that the lack of autoregulation in anom-
alous vessels may contribute to the development of macroa-
neurysms in CRMs.6 Symptomatic macroaneurysms may be
haemorrhagic or exudative.8 While spontaneous involution
of macroaneurysms with functional recovery is known, it has
been suggested that patients with subretinal haemorrhage
or exudative manifestations involving the fovea and visual
acuity deterioration should be treated to avoid irreversible
photoreceptor damage.9 Conventional laser photocoagula-
tion has been the most commonly employed treatment for
symptomatic retinal arterial macroaneurysm, however, in this
patient, the location of the macroaneurysm in the region of the
papillomacular bundle was not amenable to this form of ther-

apy. Since the development of retinal artery macroaneurysm
is associated with focal damage to arterial walls, leading to
localized ischaemia and VEGF upregulation, the use of anti-
VEGF agents has been suggested as a treatment modality.
Intravitreal bevacizumab has been shown to hasten resolution
of macular oedema and haemorrhage secondary to retinal
artery macroaneurysm, with improvement in visual acuity.10,11

Figure 1. (a) Colour fundus photograph of the left eye showing macular exudation with aberrant vessels. (b) Fundus fluorescein angiography revealing an
arterial CRM arising from the superior branch of the central retinal artery (red arrow). (c) A venous CRM was also seen draining into the inferior trunk of
the central retinal vein (blue arrow). Just temporal to the temporal margin of the optic disc, filling of a macroaneurysm along the arterial CRM was seen.
(d) Late phase showing leakage from the macroaneurysm, with multiple ill defined leaks in the nasal part of the macula.
VEGF inhibition after administration of intravitreal bevacizumab could have reduced vascular permeability, with consequent resolution of the lipid exudation and retinal oedema in our patient. This resulted in considerable improvement in visual acuity which was maintained till two years of follow up. While the CRM and macroaneurysm persisted, there was no recurrent retinal oedema or lipid exudation. This is the first report of successful treatment of visual impairment due to a macroaneurysm in an arterial CRM with intravitreal bevacizumab.

References
1. Brown GC, Donoso LA, Magargal LE, Goldberg RE, Sarin LK. Congenital retinal macrovessels. Arch Ophthalmol 1982;100:1430–6.
2. de Crecchio G, Alfieri MC, Cennamo G, Forte R. Congenital macular macrovessel. Graefes Arch Clin Exp Ophthalmol 2006;244:1183–7.
3. Mauthner L. Lehrbuch der ophthalmoscopie. Vienna: Tendler and Co; 1869, 249.
4. Kumar V, Ghosh B, Raina U, Goel N. Central serous chorioretinopathy in a patient with congenital retinal macrovessel. Can J Ophthalmol 2009;44:e57.
5. Chalam KV, Gupta SK, Vinjamaram S, Shah VA. Clinicopathologic reports, case reports, and small case series: congenital anomalous retinal artery associated with a leaking macroaneurysm. Arch Ophthalmol 2003;121:409–10.
6. Musadq M, Gibson JM. Spontaneously resolved macroaneurysm associated with a congenital anomalous retinal artery. Retin Cases Brief Rep 2010;4:70–2.
7. Koizumi H, Iida T, Mori T, Furuta M, Yannuzzi LA. Retinal arteriolar macroaneurysm and congenital retinal macrovessel. Ophthalmic Surg Lasers Imaging 2009;40:513–5.
8. Lavin MJ, Marsh RJ, Peart S, Rehman A. Retinal arterial macroaneurysms: a retrospective study of 40 patients. Br J Ophthalmol 1987;71:817–25.
9. Tsujikawa A, Sakamoto A, Ota M, Oh H, Miyamoto K, Kita M, et al. Retinal structural changes associated with retinal arterial macroaneurysm examined with optical coherence tomography. Retina 2009;29:782–92.
10. Pichi F, Morara M, Torrazza C, Manzi G, Alkabes M, Balducci N, et al. Intravitreal bevacizumab for macular complications from retinal arterial macroaneurysms. Am J Ophthalmol 2013;155:287–94.
11. Cho HJ, Rhee TK, Kim HS, Han JI, Lee DW, Cho SW, et al. Intravitreal bevacizumab for symptomatic retinal arterial macroaneurysm. Am J Ophthalmol 2013;155:898–904.